Geulah Livshits
Stock Analyst at Chardan Capital
(4.20)
# 425
Out of 5,128 analysts
246
Total ratings
46.75%
Success rate
16.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintains: Buy | $12 | $5.03 | +138.81% | 17 | Jan 6, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $26 | $7.31 | +255.68% | 14 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $110 → $174 | $96.58 | +80.16% | 6 | Dec 16, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 → $8 | $0.78 | +930.53% | 14 | Dec 12, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $17 | $9.18 | +85.19% | 13 | Dec 11, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 → $13 | $1.11 | +1,071.28% | 11 | Dec 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $74 | $56.09 | +31.93% | 16 | Nov 26, 2025 | |
| IMTX Immatics | Maintains: Buy | $25 | $9.26 | +169.98% | 3 | Nov 24, 2025 | |
| IMRX Immuneering | Maintains: Buy | $20 | $4.73 | +322.83% | 15 | Nov 13, 2025 | |
| PASG Passage Bio | Maintains: Buy | $6 → $21 | $18.00 | +16.67% | 6 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $3.87 | +132.56% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $26 | $10.39 | +150.24% | 17 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $2.59 | +556.37% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $5.30 | +183.02% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $216 → $220 | $250.60 | -12.21% | 14 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $3.80 | +189.47% | 22 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.78 | +517.98% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $1.75 | +242.86% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.11 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.24 | +466.30% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.14 | +460.75% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $34.14 | +509.26% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.01 | +1,492.04% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $14.89 | +504.43% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $4.05 | -1.23% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $20.66 | -12.88% | 1 | Oct 27, 2020 |
Taysha Gene Therapies
Jan 6, 2026
Maintains: Buy
Price Target: $12
Current: $5.03
Upside: +138.81%
4D Molecular Therapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $26
Current: $7.31
Upside: +255.68%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $110 → $174
Current: $96.58
Upside: +80.16%
Tenaya Therapeutics
Dec 12, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $0.78
Upside: +930.53%
Lexeo Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $17
Current: $9.18
Upside: +85.19%
Senti Biosciences
Dec 9, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $1.11
Upside: +1,071.28%
CRISPR Therapeutics AG
Nov 26, 2025
Maintains: Buy
Price Target: $82 → $74
Current: $56.09
Upside: +31.93%
Immatics
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $9.26
Upside: +169.98%
Immuneering
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.73
Upside: +322.83%
Passage Bio
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $18.00
Upside: +16.67%
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.87
Upside: +132.56%
Nov 7, 2025
Maintains: Buy
Price Target: $48 → $26
Current: $10.39
Upside: +150.24%
Nov 6, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $2.59
Upside: +556.37%
Nov 4, 2025
Maintains: Buy
Price Target: $15
Current: $5.30
Upside: +183.02%
Nov 4, 2025
Maintains: Buy
Price Target: $216 → $220
Current: $250.60
Upside: -12.21%
Oct 14, 2025
Maintains: Buy
Price Target: $11
Current: $3.80
Upside: +189.47%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.78
Upside: +517.98%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.75
Upside: +242.86%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.11
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.24
Upside: +466.30%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $2.14
Upside: +460.75%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $34.14
Upside: +509.26%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.01
Upside: +1,492.04%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $14.89
Upside: +504.43%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $4.05
Upside: -1.23%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $20.66
Upside: -12.88%